Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system, respiratory, and metabolic diseases. Currently, RVPH is trading at $0.44, with a target price of $0.39, indicating a potential downside of approximately -11.09%. This significant gap between the current and target price suggests a pessimistic outlook from investment analysts, leading to its exclusion from coverage.
In comparison, PDS Biotechnology Corporation (PDSB) is trading at $0.93, with a discounted cash flow (DCF) valuation of $0.54. This results in a price percentage difference of -41.72%, indicating that the stock is trading significantly above its intrinsic value. PDSB has a market cap of $43.63 million and an earnings per share (EPS) of -0.91, with a negative price-to-earnings (P/E) ratio of -1.58, reflecting its current unprofitability.
IO Biotech, Inc. (IOBT) has a current stock price of $1.17 and a DCF valuation of $0.88, leading to a price percentage difference of -24.60%. With a market cap of $77.08 million, IOBT's EPS stands at -1.58, and it has a P/E ratio of -0.63. This indicates that the stock is also trading above its intrinsic value, similar to PDSB, but with a slightly better valuation.
Skye Bioscience, Inc. (SKYE) stands out among its peers with a current stock price of $1.47 and a DCF valuation of $1.86. This results in a positive price percentage difference of 26.28%, suggesting that the stock is undervalued compared to its intrinsic value. SKYE has a market cap of $45.71 million, an EPS of -1.06, and a P/E ratio of -3.89, indicating potential growth despite current losses.
